10x Genomics (NASDAQ:TXG – Get Free Report) and Prenetics Global (NASDAQ:PRE – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.
Profitability
This table compares 10x Genomics and Prenetics Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 10x Genomics | -28.93% | -25.07% | -19.41% |
| Prenetics Global | -191.73% | -16.45% | -13.34% |
Institutional & Insider Ownership
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 25.0% of Prenetics Global shares are owned by institutional investors. 10.0% of 10x Genomics shares are owned by insiders. Comparatively, 7.8% of Prenetics Global shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 10x Genomics | 1 | 7 | 8 | 1 | 2.53 |
| Prenetics Global | 0 | 0 | 1 | 0 | 3.00 |
10x Genomics currently has a consensus target price of $25.14, indicating a potential upside of 56.07%. Prenetics Global has a consensus target price of $9.00, indicating a potential upside of 59.86%. Given Prenetics Global’s stronger consensus rating and higher probable upside, analysts plainly believe Prenetics Global is more favorable than 10x Genomics.
Valuation and Earnings
This table compares 10x Genomics and Prenetics Global”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 10x Genomics | $629.74 million | 3.10 | -$255.10 million | ($1.53) | -10.53 |
| Prenetics Global | $25.56 million | 2.01 | -$62.72 million | ($3.99) | -1.41 |
Prenetics Global has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
10x Genomics has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Prenetics Global has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500.
Summary
10x Genomics beats Prenetics Global on 9 of the 15 factors compared between the two stocks.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
